Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot open-label botulinum toxin type A biomarker study in neurogenic and idiopathic detrusor overactivity
2010-020944-37Phase 3Completed
- Sponsor
- University College London
- Start
- Feb 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of botulinum toxin type A in detrusor hyperreflexia (DH), idiopathic detrusor overactivity (IDO) and urinary incontinence (UI) (2 cohorts), sponsored by University College London. Primary endpoints: Change in urine and bladder NGF levels and Change in urothelial TRPV1 levels. Started Feb 2011; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
detrusor hyperreflexia (DH)idiopathic detrusor overactivity (IDO)urinary incontinence (UI)
Beyond the preview
Go deeper on 2010-020944-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020944-37.